ZyVersa Therapeutics, Inc.

ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA) is a clinical-stage specialty biopharmaceutical company focused on developing treatments for inflammasome- and complement-driven diseases, including rare kidney disorders. The company completed its business combination with Mana Capital Acquisition Corp., a blank-check company sponsored by Mana Capital Partners, and began trading under the ZVSA ticker in 2022. The August 2022 Form 10-Q filing reflects the company's transition to public-reporting status following the de-SPAC transaction, with operations centered on its two lead therapeutic platforms, IC 100 and VAR 200, targeting inflammatory and nephrology indications. Sign up for SpacDesk to access the full filing history, deal timeline, and sponsor data for ZVSA and hundreds of other SPAC transactions.